Defined Research To Present Results From CBD Clinical Trial For Insomnia At Sleep 2023 Medical Conference

Defined Research, Inc., a science-based wellness company announced the results of its clinical trial for Defined Sleep, a proprietary oral cannabidiol (CBD)-based formula. According to Harvard Medical School, the average U.S. worker loses 11.3 days, or $2,280, a national cost to the workforce of $63.2 billion due to insomnia. This CBD-terpene formulation resulted in an increase in both the percentage of time and the absolute time that participants spent in slow wave sleep (SWS) and REM sleep.

“The groundbreaking finding from our clinical trial is that Defined Sleep significantly increased slow wave (deep) and REM sleep by nearly one hour per night in participants suffering from severe insomnia, as measured by wrist-worn sleep-tracking devices,” stated Paul Muchowski, Ph.D., Defined Research’s CEO and founder.

Defined Research is presenting the results from the clinical trial at Sleep 2023, a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. Deep and REM sleep stages are widely thought to be critical for strengthening the immune system, increasing cell/tissue regeneration and brain metabolite clearance, and replenishing energy stores. These sleep stages are commonly referred to as “Restorative” sleep.

“It is a huge win for insomnia sufferers because they’ll finally have access to a scientifically-formulated CBD product backed by clinically validated data they can believe in. In contrast to many prescription sleep medicines and over-the-counter sleep aids, which knock you out but rob you of deep and REM sleep, this product significantly boosts those critically important sleep stages,” stated Muchowski.

Defined Sleep was developed at a GMP-certified CBD manufacturer based in Colorado, manufactured and distributed at scale with only the highest purity pharmaceutical-grade ingredients completely free of THC and other contaminants.

Photo by Thiago Patriota on Unsplash